help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerdes, M. J.
Right arrow Articles by Rowley, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerdes, M. J.
Right arrow Articles by Rowley, D. R.
Endocrinology Vol. 139, No. 8 3569-3577
Copyright © 1998 by The Endocrine Society


ARTICLES

Transforming Growth Factor-ß1 Induces Nuclear to Cytoplasmic Distribution of Androgen Receptor and Inhibits Androgen Response in Prostate Smooth Muscle Cells1

Michael J. Gerdes, Truong D. Dang, Melinda Larsen and David R. Rowley

Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030

Address all correspondence and requests for reprints to: David R. Rowley, Ph.D., Department of Cell Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030.


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Stromal-epithelial interactions in the prostate gland are dependent on androgen regulation of prostate stromal cells, yet little is known about androgen action in these cell types. Recent reports have demonstrated that androgen-regulated gene transcription can be stimulated or inhibited by certain growth factors, indicating cross-talk mechanisms. To address potential cross-talk in signaling pathways between androgen and transforming growth factor-ß1 (TGFß1) in prostate stromal cells, the PS-1 prostate smooth muscle cell line was examined. In the presence of physiological concentrations of androgen, PS-1 cell proliferation was stimulated, and androgen receptor (AR) exhibited a nuclear localization pattern. The addition of TGFß1 (25 pM) was capable of blocking androgen-induced proliferation, but had no direct effect in cultures without androgen. Immunocytochemistry to localize AR subcellular distribution showed that TGFß1 (5–100 pM) altered the distribution of AR from the nucleus to the cytoplasm. Other growth factors, including fibroblast growth factor-2, epidermal growth factor, and TGFß2 had no effect on AR distribution. The TGFß1-induced nuclear to cytoplasmic change in receptor localization was rapid (initiated within 30 min), was neutralized by TGFß1 antibodies, did not require new protein synthesis, and was complete by 6 h. Removal of TGFß1 from the culture medium resulted in a rapid redistribution of AR to the nucleus, indicating reversible mechanisms. Northern analysis of the ddp17 marker transcript for androgen action in PS-1 cells showed that androgen-stimulated ddp17 expression was inhibited in the presence of TGFß1 (25 pM). TGFß1 induced a similar nuclear to cytoplasmic distribution of AR in primary cultures of rat prostate stromal cells. TGFß1, however, had no effect on AR distribution in either the LNCaP prostatic carcinoma cell line or the DDT1MF-2 leiomyosacroma cell line. Specific cross-talk between TGFß1 and AR signaling pathways in prostate stromal cells may play a significant role in prostate development and stromal cell response in carcinoma progression.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ANDROGEN action regulates the growth, differentiation, and maintenance of the adult phenotype in the prostate gland, which is codependent on stromal-epithelial interactions (1, 2, 3, 4). Androgen receptor (AR) is initially expressed exclusively in the mesenchyme (stromal cells) of the developing urogenital sinus (3, 5, 6). Little is known regarding mechanisms of androgen action in urogenital sinus/prostate stromal cells, yet this compartment of cells mediates key androgen-regulated events in prostate gland differentiation and biology. Under androgen stimulation, mesenchyme induces an epithelial differentiation, which includes expression of AR (6, 7). A reciprocal, epithelial induction of mesenchyme has been suggested, whereby mesenchyme differentiates to periacinar, AR-positive smooth muscle cells and interglandular fibroblasts (5, 7). Accordingly, in the mature prostate gland, the smooth muscle cell type is probably the stromal cell type most responsible for androgen-induced effects in the stromal cell compartment (3, 6, 8, 9). The extent to which cross-talk mechanisms between growth factor and androgen signaling pathways influence stromal cell differentiation is not understood.

Multiple signal transduction pathways have been shown to influence steroid action, including tyrosine kinase receptors [i.e. epidermal growth factor (EGF) and insulin-like growth factor I] (10, 11), the protein kinase A pathway (12), and the protein kinase C pathway (12). Typically, these pathways lead to enhanced androgen responses and, in some instances, ligand-independent receptor activation. Moreover, certain growth factor pathways act to inhibit steroid pathways. Insulin-like growth factor II has been shown to decrease androgen-stimulated gene transcription 5-fold (11), and the addition of TGFß1 to a developing prostate organ culture model reportedly inhibited the androgen-dependent stromal induction of epithelial differentiation (8, 13). The potential linking of androgen and TGFß action have been shown in androgen deprivation studies in which TGFß1 message and protein are repressed by androgens in epithelial cells both in vitro and in vivo (14, 15, 16). The effects of TGFß1 on androgen action in prostate stromal cells may be particularly important in understanding the mechanisms of prostate carcinoma progression, where overexpression of TGFß1 by carcinoma cells (17, 18, 19) may affect tumor progression through action in the stromal compartment of cells (19). Accordingly, studies to specifically address the role of TGFß1 in androgen signaling in prostatic stromal cells are necessary to understand the complex interaction between this growth factor and androgen action pathways.

The PS-1 cell line was established and characterized to elucidate mechanisms through which androgens regulate prostate stromal cell biology. Rat ventral prostate-derived PS-1 stromal cells were positive for smooth muscle {alpha}-actin, desmin, AR (20), smooth muscle myosin heavy chain, calponin (our unpublished observations), and ps20, a new smooth muscle protein (21, 22). These data indicate that PS-1 cells are derived from a smooth muscle lineage. Proliferation of PS-1 stromal cells was growth stimulated by physiological concentrations of androgens in chemically defined, serum-free medium conditions, and several androgen-regulated marker messenger RNA (mRNA) transcripts were identified through differential display (20). Accordingly, this cell line model has the advantage of allowing examination of the expression of endogenous mRNA transcripts and cell proliferation to assess androgen action.

Our previous studies have shown that in serum-containing medium, PS-1 cells were essentially unresponsive to androgen action, and AR exhibited a cytoplasmic distribution pattern in the presence of ligand (testosterone or dihydrotestosterone) (20). In serum-free medium, however, AR was localized to the nucleus in a ligand-independent manner, and PS-1 cells were growth stimulated by physiological concentrations of androgens (10 nM) (20). These observations suggested that a serum component, possibly a peptide growth factor, was responsible for altered AR localization and activity. The data reported here show that of several growth factors tested in serum-free medium, only TGFß1 induced a nuclear to cytoplasmic shift in the distribution of AR in a specific manner coincident with an inhibition of androgen-induced proliferation and inhibited expression of transcript marker ddp17 in PS-1 cells. These studies suggest that cross-talk mechanisms between TGFß1 and AR signaling pathways may be important in directing androgen-regulated events in prostate gland stroma.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Reagents
Antibodies were obtained from the following sources: polyclonal rabbit anti-AR antibody (antibody PG-21), Affinity Bioreagents (Neshanic Station, NJ); a polyclonal rabbit anti-AR antibody (antibody U402), gift from Dr. Michael McPhaul, University of Texas (Dallas, TX); secondary fluorescein isothiocyanate-conjugated AffiniPure goat antirabbit IgG (minimal cross-reactivity to human, rat, and mouse serum proteins), Jackson ImmunoResearch Laboratories (West Grove, PA); and pan-specific TGFß neutralizing antibody, R&D Systems (Minneapolis, MN; AB-100-NA). Basal growth medium and EGF were purchased from Sigma Chemical Co. (St. Louis, MO), FCS from HyClone (Logan, UT), fibroblast growth factor-2 (FGF-2; basic FGF) and NuSerum from Collaborative Biomedical (Bedford, MA), and porcine TGFß1 and porcine TGFß2 from R&D Systems. All salts, steroids, and other reagents not mentioned were molecular biology grade from Sigma Chemical Co., and ultrapure formamide was purchased from Amresco (Solon, OH).

Cell culture
PS-1 prostate smooth muscle cell cultures were standardly maintained in Bfs medium (90% DMEM, 5% FCS, 5% NuSerum, 5 µg/ml insulin, 25 U/ml penicillin, and 25 µg/ml streptomycin) supplemented with 0.5 µg/ml testosterone in 25-cm2 flasks and incubated at 37 C with 5% CO2 as previously reported (20). Medium was replaced every 48 h with fresh medium Bfs, and cultures were passaged weekly. All experiments used PS-1 cell cultures at passages 20–27. LNCaP cells were cultured in medium L (90% RPMI 1640, 10% FBS, 0.5 µg/ml testosterone, 25 U/ml penicillin, and 25 µg/ml streptomycin). DDT1MF-2 smooth muscle cells (DDT-1/3B9 cell line provided by Dr. Dorrie Lamb, Baylor College of Medicine, Houston, TX) were cultured in medium D (low glucose 98% DMEM, 2% FBS, 25 U/ml penicillin, and 25 µg/ml streptomycin). All cultures were routinely assayed for mycoplasma contamination (MycoTect Kit, Life Technologies, Gaithersburg, MD) every 3 months.

For growth factor and steroid hormone regulation studies, cells were seeded onto sterile glass coverslips (one coverslip per well) in six-well culture plates (no. 25810, Corning, Corning, NY) in medium Bfs (PS-1 cells), medium L (LNCaP cells), or medium D (DDT1MF-2 cells) and allowed to adhere for 24–48 h. Medium was then replaced with chemically defined medium M0, which consisted of MCDB110 basal medium, 5 µg/ml insulin, 5 µg/ml transferrin, and 5 ng/ml sodium selenite (ITS), as described previously (20), and supplemented with the indicated concentration(s) of androgen or growth factor for 24–96 h as described in the text.

For studies with charcoal-stripped serum (CSS), dextran-coated charcoal was prepared by incubating 25 g charcoal (Sigma) with 0.25 g dextran T-70 in 10 mM HEPES, 0.15 M NaCl, and 1.5 mM MgCl2, pH 7.4, overnight at 4 C with stirring. Charcoal was pelleted (2000 rpm, 10 min), and an equal volume of FCS was added, mixed, and incubated overnight at 4 C in the dark. Charcoal was then pelleted (7000 rpm, 1 h, 4 C), and serum was filter sterilized. Aliquots were stored at -20 C until use.

For protein synthesis inhibition and time-course studies, cyclohexamide (10 µg/ml, final concentration) was added for 1 h before the addition of TGFß1 or androgens, and cells were cultured for 30 min to 24 h before fixation. Control cultures did not receive cyclohexamide. Coverslips were removed from culture at the indicated time points and immediately fixed with 10% neutral buffered formalin for 20 min at room temperature, washed three times (5 min each time) in PBS, and stored in 70% ethanol at 4 C before immunohistochemistry. Additionally, replicate coverslips were fixed with 4% paraformaldehyde, which produced identical immunocytochemical results as with formalin fixation. The efficiency of cyclohexamide to inhibit protein synthesis was determined by [35S]methionine incorporation in cell lysates as follows. PS-1 cells were seeded as described above in triplicate in 24-well culture dishes in medium Bfs for 24 h. Medium was changed to defined medium M0 and 10 µg/ml cyclohexamide for 1 h before the addition of [35S]methionine (20 µCi/ml), dihydrotestosterone (DHT; 10 nM) and TGFß1 (25 pM). Cell lysates were harvested at 1 and 6 h and precipitated with equal volumes of 20% TCA as reported previously (23). Lysates were transferred to Whatman glass-fiber filters (Whatman, Clifton, NJ), washed three times in ice-cold ethanol, and quantitated by scintillation counting to allow determination of the percentage of protein synthesis inhibition (23). For studies using a pan-specific neutralizing antibody for TGFß1 (ND50 = 5 µg/ml), cells were cultured as described above, and 10–50 µg/ml of antibody were added at the time of TGFß1 addition.

Primary cultures of rat ventral prostate stromal cells were established as we have reported previously for the initiation of the U4F and PS-1 cell lines (20, 24). Briefly, organ explant cultures were seeded adjacent to coverslips in medium Bfs. Primary stromal cultures were observed extending onto the coverslips after 1 week of culture. Medium was changed to defined medium M0 for 24 h, followed by supplementation with the indicated concentration(s) of androgen or TGFß1 for 24 h as described in the text and Fig. 5Go. Cultures were fixed and processed for immunocytochemistry as described above for the PS-1 cell line.



View larger version (47K):
[in this window]
[in a new window]
 
Figure 5. Effects of TGFß1 on AR distribution in primary cultures of rat prostate stromal cells. Primary cultures of stromal cells from rat ventral prostate were established as described in Materials and Methods and exposed to conditions identical to those described in Fig. 1Go. A, Cultures in serum-free medium containing DHT (10 nM). B, Cultures in medium containing DHT (10 nM) and TGFß1 (25 pM).

 
Cell proliferation assays
Cell proliferation assays were performed as described previously (20). Briefly, PS-1 cells were seeded in triplicate 24-well plates at 9.6 x 103 cells/cm2 (1.82 x 104 cells/well) in medium Bfs (containing serum) and allowed to adhere for 24 h; medium was replaced with chemically defined medium M0 (serum free, steroid free) for 24 h, then replaced with fresh medium M0 containing 10 nM DHT and/or 50 pM TGFß1. Vehicle control (each well received 0.05% ethanol, final concentration) was added to all control (minus steroid) cultures. The cell number per well was determined every 24 h. For cell counting, medium was removed, and cells were exposed to trypsin-EDTA (0.25% trypsin and 0.025% EDTA in calcium, magnesium-free HBSS) for 4 min and neutralized by the addition of serum, cells were counted with an improved Neubauer-type hemocytometer (eight squares counted per well, triplicate wells per experimental regimen), and data were expressed as the mean number of cells per well ± SEM in all experiments. Each experiment was repeated three times with triplicate wells per treatment regimen per experiment analyzed. The statistical significance of differential results at each time point for each experiment was determined by Student’s t test.

Immunocytochemistry
Cells were seeded into six-well culture dishes containing sterile glass coverslips at a density of 9.6 x 103 cells/cm2 and allowed to adhere for 48 h in fresh serum-containing (Bfs, L, or D) medium. Medium was then changed to basal M0 medium (serum free, steroid free) for 24 h, followed by the experimental conditions described in the text and figures. Coverslips were washed three times in PBS and fixed in 10% neutral buffered formalin as described above. Cells were permeablized by exposure to 0.1% Triton X-100 for 5 min in PBS at room temperature, washed three times (5 min each time) in PBS, and incubated with anti-AR antibody PG-21 (1:60 dilution) or anti-AR antibody U402 (1:100 dilution) in PBS containing 1% BSA for 24 h at 37 C. Coverslips were then washed sequentially in PBS, followed by PBS-0.1% Triton X-100, followed by PBS for 15 min/wash at room temperature on a rocking platform. Secondary antibody staining consisted of fluorescein isothiocyanate-conjugated goat antirabbit IgG (1:100 dilution of 1.5 mg/ml stock) in PBS-1% BSA for 45 min at 37 C. All coverslips for each hormone/growth factor regimen were prepared in triplicate, and replicate experiments were repeated on at least 2 separate days. Coverslips were washed as described above and mounted onto glass slides with antifade mounting solution [250 µg/ml diazabicyclo-(2,2,2)octane in PBS-glycerol, 1:9]. Photomicroscopy was performed on a Nikon Labophot-2 equipped for fluorescence (Nikon, Melville, NY) using TMAX ASA 400 film or Ektachrome ASA 400 color slide film (Eastman Kodak, Rochester, NY). To confirm immunocytochemistry data, Western analysis of AR was performed using anti-AR antibody PG-21, and total cell lysates of PS-1 cells were cultured as described in the text following standard Western blot procedures that we have published previously (22). A primary reactive species was observed at 111 kDa. The experiment was repeated in triplicate.

DNA probes
The ddp17 probe was prepared by digesting 10 µg plasmid pCRII-ddp17 (20) with EcoRI (2 U/µg; Promega, Madison, WI) at 37 C for 3 h. The 390-bp insert was purified by gel electrophoresis, excised from a 1.2% agarose gel (Amresco), and prepared for labeling with the QIAquick gel extraction kit (Qiagen, Chatsworth, CA). Seventy nanograms of insert DNA were random prime labeled following the manufacturer’s protocols (Random Prime labeling kit, Boehringer Mannheim, Indianapolis, IN) with [32P]deoxy-CTP (3000 Ci/mmol; New England Nuclear, Boston, MA) at 37 C for 3 h and purified with the QIAquick nucleotide removal kit according to the manufacturer’s protocols (Qiagen).

RNA analysis
PS-1 cells were seeded into 75-cm2 flasks in medium Bfs for 24 h, after which medium was changed to M0 (serum free, chemically defined) for 24 h, followed by the experimental conditions described in the text. Total RNA was isolated by extracting cells with RNA Stat-60 essentially according to manufacturer’s suggested protocols. RNA was fractionated with a 1.2% agarose gel containing 3.3 M formaldehyde and 20 mM NaPO4 (pH 7) at 30 V for 17 h in 20 mM NaPO4 running buffer (circulated throughout run). Loading accuracy was determined by ethidium bromide staining of gels. RNA was transferred to Nytran membranes by capillary transfer with a SSC (standard saline citrate) gradient (Schleicher and Schuell, Keene, NH). RNA was UV cross-linked to the membrane, prehybridized (5 x SSC, 50% formamide, 0.1% SDS, 50 mM NaPO4 (pH 7.0), and 1 µg/ml salmon sperm DNA) for 24 h, and then hybridized with 1 x 106 cpm/ml [32P]deoxy-CTP random prime-labeled probe overnight at 42 C. Membranes were washed twice for 30 min each time in 2 x SSC-0.1% SDS at room temperature with agitation, followed by two 20-min washes in 0.2 x SSC-0.1% SDS at 65 C. Membranes were exposed to radiographic film for 24–48 h. Transfer efficiency was determined by methylene blue staining of blots.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Previous studies have characterized the PS-1 rat prostate smooth muscle cell line, including smooth muscle markers, AR, androgen-responsive growth in serum-free, chemically defined medium, and the identification of androgen-regulated mRNA transcripts (20). PS-1 cells in serum-containing medium were relatively unresponsive to androgen, whereas proliferation of cultures in chemically defined, serum-free medium was stimulated by androgen. Initial characterization of the PS-1 cell line showed a ligand-independent nuclear localization of AR in cells cultured in chemically defined medium, whereas a cytoplasmic localization was observed in cells cultured in serum-containing medium (20). To assess whether specific growth factors could affect AR distribution patterns and androgen response, PS-1 cells were cultured in serum-free medium supplemented with various growth factors [FGF-2 (basic FGF), EGF, TGFß1, or TGFß2] and compared with control cultures in serum-containing medium.

PS-1 control cultures in serum-containing medium Bfs (5% FCS and 5% NuSerum) exhibited a cytoplasmic AR localization with a uniformly diffuse perinuclear distribution, as shown in Fig. 1AGo. Testosterone concentrations ranging from 10 nM to 1 µM did not affect the cytoplasmic AR localization pattern in serum-containing medium (Fig. 1BGo). Further, as CSS has been frequently used as a steroid-free serum source, both 10% and 1% CSS were tested with and without androgens. In medium with 10% CSS, a cytoplasmic AR distribution pattern was observed, identical to patterns in medium Bfs. Cultures in medium plus 1% CSS exhibited some nuclear accumulation of AR, however not to the extent previously observed with chemically defined medium conditions. These results are summarized in Table 1Go.



View larger version (144K):
[in this window]
[in a new window]
 
Figure 1. Effects of different growth media on AR localization in PS-1 cells. PS-1 cells were seeded onto glass coverslips in serum-containing medium (Bfs) for 24 h, medium was changed to chemically defined, serum-free medium M0 (MCDB110 + ITS) for 24 h, then medium was changed to regimens A–H for 24 h as described. Cultures were fixed, and AR distribution was determined by immunocytochemistry as described in Materials and Methods. A, Medium Bfs; B, Bfs supplemented with testosterone (1 µM); C, basal (serum-free) medium M0; D, basal medium M0 supplemented with DHT (10 nM); E, basal medium M0 supplemented with TGFß1 (25 pM); F, basal medium M0 supplemented with TGFß1 (25 pM) and DHT (10 nM); G, same as in E, with the addition of a pan-specific neutralizing antibody (10 µg/ml) to TGFß; H, same as in E, with the addition of cyclohexamide (10 µg/ml) 1 h before TGFß1 addition and a further incubation of 8 h. Magnification, x1120.

 

View this table:
[in this window]
[in a new window]
 
Table 1. Relative intracellular distribution of AR in PS-1 cells

 
To test specific growth factors in serum-free conditions, PS-1 cells were seeded in serum-containing Bfs medium and allowed to attach for 24 h, and then medium was changed to serum-free M0 basal medium for 24 h before the addition of growth factor. As shown in Fig. 1CGo, the 24-h period in unsupplemented medium M0 induced a nuclear distribution of AR and thus allowed for growth factors that might affect nuclear localization of AR to be identified under these assay conditions. PS-1 cells cultured in either vehicle control or 10 nM DHT or for 1–7 days in medium M0 produced identical nuclear AR patterns (Fig. 1DGo). Identical patterns were observed using either the PG-21 or U402 anti-AR antibodies for immunocytochemistry as described in Materials and Methods. These data indicate that androgens are not required in defined M0 medium for AR to localize to the nucleus in PS-1 stromal cells. PS-1 cultures in M0 serum-free medium supplemented with FGF-2 (5 ng/ml), EGF (10 ng/ml), or TGFß2 (10–200 pM) also exhibited nuclear AR staining patterns identical to those of cultures in the unsupplemented basal medium alone (see Table 1Go; localization pattern identical to that in Fig. 1CGo). Nuclear localization patterns were also ligand independent for each growth factor tested (Table 1Go). In contrast, PS-1 cells cultured in basal M0 medium supplemented with TGFß1 (5–100 pM for 24 h) exhibited a cytoplasmic distribution pattern of AR as shown in Fig. 1EGo (25-pM TGFß1 concentration shown), also independent of ligand concentration (0–1 µM DHT; Fig. 1FGo). Nuclear AR was not detectable in any cultures containing TGFß1. TGFß1 at 5 pM produced a near-complete cytoplasmic distribution of AR, and all higher concentrations up to 100 pM produced a complete redistribution of AR. The cytoplasmic localization pattern of AR induced by TGFß1 was distinct from that observed in serum-containing medium. The TGFß1-induced pattern exhibited a considerably more filamentous pattern of localization (Fig. 1Go, E compared with A and B).

To address the specificity of the TGFß1 response, a pan-specific neutralizing antibody to TGFß1 (R&D Systems) was used. PS-1 cultures that received both TGFß1 (25 pM) and neutralizing antibody (10 µg/ml) exhibited a nuclear localization of AR, as shown in Fig. 1GGo (compare with Fig. 1Go, E and F). Control cultures receiving antibody alone exhibited no effect (data not shown). To assess whether the cytoplasmic AR localization previously observed in serum-containing medium might be attributed to TGFß1 activity in serum, TGFß1 neutralizing antibody was added to serum-containing cultures. Under these conditions, a cytoplasmic localization pattern was retained regardless of the antibody concentration (10–50 µg/ml; data not shown). These results suggest that serum-induced cytoplasmic localization of AR is not due to TGFß1 activity and that other serum components, in addition to TGFß1, act to influence the cellular distribution of AR in PS-1 cell cultures.

To determine whether the TGFß1-induced effects on AR distribution are directly downstream of a signaling event or are mediated through newly synthesized intermediary proteins, PS-1 cells were cultured with or without TGFß1 in medium containing cyclohexamide. The addition of cyclohexamide (10 µg/ml) in the absence of TGFß1 did not alter the nuclear localization of AR observed in control cultures (data not shown). The addition of cyclohexamide (10 µg/ml) and TGFß1 (25 pM) together in either the presence or absence of androgen (DHT, 10 nM) resulted in the usual cytoplasmic localization pattern, as shown in Fig. 1HGo. Cyclohexamide treatment under these conditions produced 95.3% and 94.2% decreases in [35S]methionine incorporation in cell lysate proteins in PS-1 cultures (treated for 1 and 6 h, respectively), indicating a nearly complete absence of new protein synthesis. These results indicate that TGFß1-induced mechanisms for localizing AR from the nucleus to cytoplasm in PS-1 cells is independent of new protein synthesis.

To assess the time course of the TGFß1-induced shift of nuclear to cytoplasmic AR, a series of time points was examined after the addition of TGFß1 (25 pM). An increase in cytoplasmic AR staining intensity was apparent after 1 h of incubation with TGFß1, as shown in Fig. 2AGo. More extensive filamentous cytoplasmic staining pattern and staining intensity were apparent at 3 h (shown in Fig. 2BGo). The majority of AR was cytoplasmic at the 6 h point (Fig. 2CGo), and the typical cytoplasmic AR distribution pattern, with nuclei essentially void of AR, was observed after 24 h (Fig. 2DGo). At 24 h, medium was changed to basal conditions (medium M0) without TGFß1 to determine reversibility. Within 1 h after the withdrawal of TGFß1, a nuclear staining pattern of AR was again apparent (Fig. 2EGo), and redistribution of AR to the nucleus was complete by 6 h (Fig. 2FGo). Identical time-course patterns and reversibility were observed in medium without androgen or in medium containing cyclohexamide (10 µg/ml; data not shown).



View larger version (149K):
[in this window]
[in a new window]
 
Figure 2. Time course of TGFß1-induced nuclear to cytoplasmic shift in AR distribution. PS-1 cells were seeded on glass coverslips in Bfs medium for 24 h. Medium was changed to chemically defined M0 basal medium for 24 h, followed by the addition of TGFß1 (25 pM) at the specified time points (A–D). To assess reversal of the response, replicate PS-1 cultures exposed to TGFß1 (25 pM) for 24 h were switched to medium M0 for the indicated times (E and F). All cultures were fixed and immunostained for AR as described in Fig. 1Go. A, 1 h of TGFß1; B, 3 h of TGFß1; C, 6 h of TGFß1; D, 24 h of TGFß1; E, 24 h of TGFß1 plus 1-h wash in M0; F, 24 h of TGFß1 plus 6-h wash in M0. Magnification, x1120.

 
To determine whether the TGFß1-induced shift of AR distribution altered androgen-regulated events, PS-1 cells were assayed for alterations in androgen-induced cell proliferation and expression of ddp17 marker transcript in the presence and absence of TGFß1. The PS-1 cell line was previously shown to be growth stimulated by androgen (10 nM DHT) in chemically defined, serum-free medium M0 (20). Figure 3Go shows a representative growth-response curve for PS-1 cells stimulated by 10 nM DHT compared with that for cells treated with a steroid-free vehicle control, TGFß1, or TGFß1 plus DHT over a 6-day course. DHT (10 nM) acted to significantly (p < 0.01) stimulate the proliferation of PS-1 cells as reported previously (20). The addition of TGFß1 (25 pM) together with DHT (10 nM) produced a consistent (n = 3 separate experiments) and significant inhibition (p < 0.01) of cell proliferation relative to that of DHT only (10 nM) cultures. No consistent significant differences were noted between the control (minus androgen) and TGFß1 plus DHT cultures. In addition, TGFß1 in the absence of androgens did not alter the proliferation rate of PS-1 cells. These data suggest that TGFß1-induced inhibition of PS-1 cells is mediated through a block of androgen response in defined medium conditions.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 3. Effects of androgen and TGFß1 on PS-1 cell proliferation. PS-1 cells were seeded into 96-well plates in medium Bfs for 24 h. Medium was then changed to basal medium M0, basal medium M0 plus 10 nM DHT, basal medium M0 plus TGFß1, or basal medium M0, TGFß1, and 10 nM DHT. Cells from triplicate wells for each experiment were trypsinized and counted every 24 h as described in Materials and Methods. Shown is the mean cell number (±SEM) of a representative curve of three separate experiments.

 
In addition to proliferation responses, PS-1 cells were examined for TGFß1-induced changes in androgen-regulated mRNA expression. PS-1 cultures in medium containing TGFß1 in the absence or presence of DHT (10 nM) were probed for ddp17 mRNA expression, an androgen-regulated transcript in PS-1 cells, as reported previously (20). As shown in Fig. 4Go, and rogen-induced ddp17 expression (lane 2) was inhibited by TGFß1 (25 pM) to basal levels (lanes 1 and 4). TGFß1 alone did not alter basal expression of ddp17 in androgen-free medium (lanes 1 and 3). To address the possibility that TGFß1 may induce a change in AR protein levels concurrent with a redistribution of AR, Western analysis of AR in total cell lysates from each of the experimental conditions was examined. No changes in AR content, as determined by Western analysis at two different protein concentrations (n = 3 experiments), was detectable under any of the experimental conditions (data not shown). These data are consistent with the staining intensity observed with immunocytochemistry, which suggested no overall alteration in AR protein levels.



View larger version (57K):
[in this window]
[in a new window]
 
Figure 4. Effects of androgen and TGFß1 on ddp17 expression. PS-1 cells were seeded in medium Bfs for 24 h, then medium was changed to basal medium M0 for an additional 24 h. Cultures were changed to medium M0 with and without DHT (10 nM) or TGFß1 (25 pM), as indicated for each lane, for 24 h. RNA was harvested and used for Northern analysis of ddp17 mRNA expression (upper panel) as described in Materials and Methods. Loading accuracy and efficiency of transfer were determined by ethidium bromide staining of gels and methylene blue staining of total RNA transferred to membranes, as shown in the bottom panel.

 
To examine TGFß1 effects on other androgen-regulated cell lines, primary cultures of rat prostate stromal cells and both an epithelial cell line, LNCaP (prostate cancer carcinoma cell line), and a stromal cell line, DDT1MF-2 (vas deferens leiomyosarcoma cell line), were analyzed for TGFß1-induced alterations in AR distribution. As shown in Fig. 5Go, primary cultures of rat ventral prostate stromal cells in defined medium M0 plus DHT (10 nM) showed a TGFß1 (25 pM)-induced cytoplasmic distribution of AR nearly identical to the altered distribution observed in the PS-1 cell line. In contrast to either PS-1 cells or primary stromal cultures, LNCaP cells cultured with TGFß1 (25 pM) and androgen (10 nM or 1 µM) maintained a nuclear distribution of AR with no apparent cytoplasmic redistribution of AR (data not shown). Also different from PS-1 cells, LNCaP cells cultured in defined medium (medium M0) without androgen exhibited a cytoplasmic distribution of AR. Supplementation of medium with androgen (10 nM or 1 µM) resulted in a nuclear localization of AR. Similarly, DDT1MF-2 cells exhibited a nuclear AR distribution in medium (M0) supplemented with androgen (10 nM or 1 µM), which did not redistribute to the cytoplasm in response to TGFß1 (25 pM). However, when DDT1MF-2 cells were tested in medium containing cyclohexamide (10 µg/ml), a diminished nuclear staining was apparent, with an increase in cytoplasmic staining in the presence of TGFß1 (data not shown). This shift in AR distribution was not to the extent observed in PS-1 cells or primary stromal cell cultures. In contrast, no alterations in AR distribution were noted when LNCaP cells were cultured with cyclohexamide and TGFß1.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
These studies show that TGFß1 induces a nuclear to cytoplasmic distribution of AR with an uncoupling of the proliferative response to androgen and expression of the ddp17 androgen-regulated message in PS-1 prostate smooth muscle cells. The TGFß1-induced process was rapid, was fully reversible, did not require new protein synthesis, and was neutralized by TGFß1 antibody. To our knowledge, this response to TGFß1 represents a novel activity ascribed to this growth factor. These data suggest that TGFß1 is a potent regulator of androgen action in prostate smooth muscle cells through changing distribution pattern of AR.

As only cell proliferation and the expression of ddp17 marker has been examined here, and little else is known about the androgen response in PS-1 cells, it is possible that not all effects of androgen are modulated by TGFß1. In addition, the observation that TGFß1 alters the distribution of AR in primary cultures of rat prostate stromal cells indicates that this response is not simply a unique feature of the PS-1 cell line. Rather, these results suggest that this response to TGFß1 is probably a central feature of prostate stromal cells in general. The cell type lineage of the PS-1 cell line or the primary stromal culture outgrowths is not known; however, all of the primary culture cells were AR positive. These data suggest the possibility of a selection pressure in the androgen-containing Bfs medium in selecting an AR-positive stromal cell outgrowth. Due to the lack of additional cell lines that are both androgen responsive and TGFß1 responsive, it is difficult to comment further on the cell type specificity of this response. The full extent to which TGFß1 regulates androgen action in vitro or in vivo is not yet known. Accordingly, the PS-1 stromal cell line will be beneficial to future studies to determine mechanisms of steroid receptor shuttling and translocation due to the regulatable nature of AR distribution within this cell. Additionally, this cell model system may aid in identifying specific cross-talk mechanisms between TGFß1 and androgen signal transduction.

Expression patterns and functional studies suggest that TGFß1 plays a major role in prostate gland development and cancer progression. However, the specific mechanisms of action, primary target cell types, and overall functional significance of TGFß1 action in the prostate are not known. In the rat coagulating gland (anterior prostate gland) morphogenesis model, TGFß1 reportedly inhibited the development of glandular differentiation (8, 13), a process fully dependent on androgen signaling in mesenchyme/stromal cells (8). Furthermore, TGFß1 acted to inhibit androgen-induced penile growth during development without reducing AR content in the tissue (25). The data presented here suggest that the development inhibitory action of TGFß1 in androgen-responsive tissues may be mediated through altered AR distribution and androgen response.

The role of elevated TGFß1 expression by prostate carcinoma cells (17, 18, 19) is also not known. In prostate cancer, TGFß receptor type II is maintained in stromal cells (19), whereas TGFß receptors are down-regulated in epithelial carcinoma cells (19, 26, 27, 28). Hence, TGFß1 action may be mediated through the stromal compartment of cells in prostate cancer progression. TGFß1 may regulate stromal cells to provide a stromal environment more supportive of carcinoma proliferation and invasion. A TGFß1-induced change in stromal cell response to androgen may be a central component of this process.

Specific cross-talk mechanisms of TGFß1-induced changes in AR distribution are not yet known. Cyclohexamide experiments indicate that new protein synthesis is not required, suggesting a direct effect on signal transduction events. Changes in AR phosphorylation status as a consequence of TGFß1 signaling may play a role. It has been well documented that steroid receptor phosphorylation alters transcriptional activity (29, 30, 31, 32, 33). Although no known phosphorylation sites in AR have been shown to influence nuclear localization or shuttling of receptor from nucleus to cytoplasm, several sites with unknown function have not yet been examined for directing receptor distribution (29, 32). It is possible that TGFß1 acts to alter the balance of constitutive shuttling of AR, where the nuclear export rate is more rapid than the import rate. Nuclear export of steroid hormone receptors is believed to be constitutive, although may vary between cell types (34, 35). TGFß1 may also regulate either a nuclear export factor or a cytoplasmic anchoring factor, such as heat shock protein 56 (hsp56). With the glucocorticoid receptor, cytoplasmic colocalization with microtubules is mediated through hsp56 (36, 37), and hsp56 is required for nuclear shuttling (38). The cytoplasmic pattern of AR staining induced by TGFß1 exhibited a filamentous network similar to a microtubule network observed with the glucocorticoid receptor. This concept is further supported by the fact that hsp56 has been reported in the AR-hsp complex (33, 39).

Of interest, the nuclear localization of AR in serum-free medium was not dependent on androgen with PS-1 cells. Nuclear localization of steroid receptors in the absence of hormone appears to be tissue and receptor type specific. Both estrogen and progesterone receptors typically show a nuclear distribution regardless of hormone (40, 41). In contrast, glucocorticoid receptors exhibit both nuclear and cytoplasmic distributions in the absence of hormone (42). The distribution pattern of AR in response to androgen is reported to be tissue and cell type specific in vivo. The lateral lobe of the rat prostate exhibited a nuclear AR pattern in both intact and castrate animals, whereas the ventral and dorsal lobes showed a gradual switch from nuclear to cytoplasmic with castration, the rate of which was region dependent, with the distal tips exhibiting a slower loss of nuclear AR (43, 44, 45). Regardless of the nuclear or cytoplasmic distribution pattern, all prostate tissue exhibited the typical castration-induced involution (43, 44). It has been suggested by Wilson and colleagues (43) that androgen serves to anchor or make more stable the interaction of AR with nuclear elements in some cell types and is permissive to nuclear transport, if not an absolute requirement. Together these studies indicate that the effect of androgen withdrawal on the distribution of AR in vivo is complex and probably cell type specific and tissue specific, with no clear-cut dogma on the effects of androgen on AR distribution being universally applicable to all androgen-responsive cell types.

Our data suggest that the possible anchoring of AR in the nucleus of PS-1 cells is destabilized by TGFß1 signaling as well as other unknown serum components. The effect of serum to induce a cytoplasmic distribution pattern of steroid receptors has been observed in other cell systems. Both human and rat vascular smooth muscle cultures exhibited a cytoplasmic localization of estrogen receptor when cultured in medium containing CSS (46, 47). Many model cell systems have reportedly required serum-free medium to exhibit a steroid response. Additionally, the recently reported DuK50 prostate stromal cell line was androgen insensitive in high serum-containing medium, yet exhibited androgen-stimulated proliferation in low serum medium (48). The data reported here may help to explain the lack of steroid hormone response generally observed with cells cultured in serum-containing medium, in contrast to specific responses generated in serum-free conditions.

TGFß1 did not affect AR distribution patterns in LNCaP carcinoma cells. The proliferation of LNCaP human prostatic carcinoma cells is stimulated by androgens; however, LNCaP cells express a mutated AR at higher levels than normal prostate gland (49, 50). The responsivity of LNCaP cells to TGFß1 and the role of androgens in a putative TGFß1 response are complex and not well understood. The majority of reports have shown that TGFß1 does not affect LNCaP cells (51, 52, 53, 54) that lack TGFß receptor type I (51) and lack high affinity binding sites to TGFß1 (53). In contrast, two other reports have shown that LNCaP cells are growth inhibited by TGFß1 only in the presence of specific concentrations of androgen (55) and in a dose-dependent manner (56). Moreover, TGFß1 has been shown to block EGF- and TGF{alpha}-induced proliferation of LNCaP cells (57, 58) and to increase prostatic acid phophatase and AR levels (57). Hence, it is not clear whether the inability of TGFß1 to affect AR distribution in LNCaP cells results from altered TGFß1 signaling, mutations in AR, or other alterations in AR shuttling mechanisms.

TGFß1 did stimulate DDT1MF-2 cells to redistribute some AR immunoreactivity from the nucleus to the cytoplasm, however only in the presence of cyclohexamide. These data suggest that maintained nuclear AR in TGFß1-treated DDT1MF-2 cells probably resulted from new AR synthesis. The DDT1MF-2 stromal cell line was derived from a hamster ductus deferens leiomyosarcoma, is AR positive, and exhibits androgen-stimulated proliferation as well as androgen-stimulated FGF-1 expression (59, 60, 61). In contrast to DDT1MF-2 cells, PS-1 cells exhibited a major loss of nuclear AR, and a cytoplasmic redistribution regardless of whether cyclohexamide was present. One possible explanation for these data is that PS-1 cells may have a lower AR degradation rate and/or a lower AR synthesis rate relative to DDT1MF-2 cells.

In evaluation of these data it should be kept in mind that of the three cell lines and primary cultures tested in the present study, only the PS-1 stromal cell line and primary stromal cell cultures were derived from normal (noncancerous) tissue (20). In addition, it is clear that TGFß1 generally induces apoptosis in epithelial cells, whereas TGFß1 is growth stimulatory to many stromal cell lines. Moreover, the differences in TGFß receptor types and content between these different cell lines are not known. How the differential TGFß1 responses in AR distribution relate to fundamental biological differences in cancer vs. noncancer cells or in epithelial cells vs. stromal cells is not yet clear.

The PS-1 cell culture model system will be useful for studies on TGFß1 and androgen mechanisms to better understand androgen action in the prostate smooth muscle cell type. Future studies can be directed to determine specific cross-talk mechanisms, cell type specificity, physiological relevance to prostate morphogenesis, and the stromal cell response in prostate cancer progression.


    Footnotes
 
1 This work was supported by NIH Grants DK-45909, CA-58093, and CA-58204 and a grant from Sheffield Pharmaceuticals. Back

Received December 29, 1997.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Cunha GR, Chung LWK 1981 Stromal-epithelial interactions. I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J. Steroid Biochem 14:1317–1321
  2. Chung LWK, Cunha GR 1983 Stromal-epithelial interactions. II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 4:503–511[Medline]
  3. Cunha GR, Hayward SW, Dahiya R, Foster BA 1996 Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat 155:63–72[Medline]
  4. Bonkhoff H, Remberger K 1996 Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28:98–106[CrossRef][Medline]
  5. Cooke PS, Young P, Cunha GR 1991 Androgen receptor expression in developing male reproductive organs. Endocrinology 128:2867–2873[Abstract]
  6. Prins GS, Birch L 1995 The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 136:1303–1314[Abstract]
  7. Prins GS, Cooke PS, Birch L, Donjacour AA, Yalcinkaya TM, Siiteri PK, Cunha GR 1992 Androgen receptor expression and 5{alpha}-reductase activity along the proximal-distal axis of the rat prostatic duct. Endocrinology 130:3066–3073[Abstract]
  8. Cunha GR 1994 Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer [Suppl] 74:1030–1044
  9. Prins GS, Birch L, Greene GL 1991 Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 129:3187–3199[Abstract]
  10. Reinikainen P, Palvimo JJ, Janne OA 1996 Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137:4351–4357[Abstract]
  11. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474–5478[Abstract/Free Full Text]
  12. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA 1994 Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 135:1359–1366[Abstract]
  13. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA 1992 Normal and abnormal development of the male urogenital tract: role of androgens, mesenchymal-epithelial interaction and growth factors. J Androl 13:465–475[Abstract/Free Full Text]
  14. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C 1996 Expression and localization of transforming growth factor-ß receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol 10:107–115[Abstract]
  15. Kyprianou N, Isaacs JT 1989 Expression of transforming growth factor-ß in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515–1522[Abstract]
  16. Kyprianou N, Isaacs JT 1988 Identification of a cellular receptor for transforming growth factor-ß in rat ventral prostate and its negative regulation by androgen. Endocrinology 123:2124–2131[Abstract]
  17. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH 1992 Transforming growth factor ß 1 as a biomarker for prostate cancer. J Cell Biochem 16H:54–61
  18. Steiner MS, Zhou Z-Z, Tonb DC, Barrack ER 1994 Expression of transforming growth factor-ß1 in prostate cancer. Endocrinology 135:2240–2247[Abstract]
  19. Gerdes MJ, Larsen M, McBride L, Dang TD, Lu B, Rowley DR 1998 Localization of transforming growth factor ß 1 and type II receptors in developing normal human prostate and carcinoma tissues. J Histochem Cytochem 46:379–388[Abstract/Free Full Text]
  20. Gerdes MJ, Dang TD, Lu B, Larsen M, McBride L, Rowley DR 1996 Androgen-regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS-1). Endocrinology 137:864–872[Abstract]
  21. Rowley DR, Dang TD, Larsen M, Gerdes MJ, McBride L, Lu B 1995 Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J Biol Chem 270:22058–22065[Abstract/Free Full Text]
  22. Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR 1998 Molecular cloning and expression of ps20 growth inhibitor: a novel WAP-type "four disulfide core" domain protein expressed in smooth muscle. J Biol Chem 273:4574–4584[Abstract/Free Full Text]
  23. Rowley DR, Tindall DJ 1987 Responses of NBT-II bladder carcinoma cells to conditioned medium from normal fetal urogenital sinus. Cancer Res 47:2955–2960[Abstract/Free Full Text]
  24. Rowley DR 1992 Characterization of a fetal urogenital sinus mesenchymal cell line U4F: secretion of a negative growth regulatory activity. In Vitro Cell Dev Biol 28:29–38
  25. Gelman J, Garban H, Shen R, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid N 1998 Transforming growth factor ß1 (TGF-ß1) in penile and prostate growth in the rat during sexual maturation. J Androl 19:50–57[Abstract/Free Full Text]
  26. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C 1996 Loss of expression of transforming growth factor ß type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255–1261[Abstract]
  27. Gou Y, Jacobs SC, Kyprianou N 1997 Down-regulation of protein and mRNA expression for transforming growth factor-ß (TGF-ß1) type I and type II receptors in human prostate cancer. Int J Cancer 71:573–579[CrossRef][Medline]
  28. Williams RH, Stapleton AMF, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC 1996 Reduced levels of transforming growth factor ß receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 2:635–640[Abstract]
  29. Kemppainen JA, Lane MV, Sar M, Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J Biol Chem 267:968–974[Abstract/Free Full Text]
  30. Zhou Z, Kemppainen JA, Wilson EM 1995 Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605–615[Abstract]
  31. O’Malley B 1990 The steroid receptor superfamily: more excitement predicted for the future. Mol Endocrinol 4:363–369[Medline]
  32. Zhou Z, Kemppainen JA, Wilson EM 1995 Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605–615
  33. Smith DF, Toft DO 1993 Steroid receptors and their associated proteins. Mol Endocrinol 7:4–11[CrossRef][Medline]
  34. Madan AP, DeFranco DB 1993 Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc Natl Acad Sci USA 90:3588–3592[Abstract/Free Full Text]
  35. Chandran UR, DeFranco DB 1992 Internuclear migration of chicken progesterone receptor, but not simian virus-40 large tumor antigen, in transient heterokaryons. Mol Endocrinol 6:837–844[Abstract]
  36. Akner G, Wilkstrom A-C, Gustafsson J-A 1994 Subcellular distribution of the glucocorticoid receptor and evidence for its association with microtubules. J Steroid Biochem Mol Biol 52:1–55
  37. Czar MJ, Owens-Grillo JK, Yem AW, Leach KL, Deibel MR, Welsh MJ, Pratt WB 1994 The hsp56 immunophilin component of untransformed steroid receptor complexes is localized both to microtubules in the cytoplasm and to the same nonrandom regions within the nucleus as the steroid receptor. Mol Endocrinol 8:1731–1741[Abstract]
  38. Czar MJ, Lyons RH, Welsch MJ, Renoir J, Pratt WB 1995 Evidence that the fk506-binding immunophilin heat shock protein 56 is required for trafficking of the glucocorticoid receptor from the cytoplasm to the nucleus. Mol Endocrinol 9:1549–1560[Abstract]
  39. Tai P-K, Maeda Y, Nakao K, Wakim NG, Duhring JL, Faber LE 1986 A 59-kilodalton protein associated with progestin, estrogen, androgen, and glucocorticoid receptors. Biochemistry 25:5269–5275[CrossRef][Medline]
  40. King WJ, Greene GL 1984 Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745–747[CrossRef][Medline]
  41. Guiochon-Mantel A, Loosfelt H, Lescop P, Sar S, Atger M, Perrot-Applanat M, Milgrom E 1989 Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers. Cell 57:1147–1154[CrossRef][Medline]
  42. Wikstrom AC, Bakke O, Okret S, Bronnegard M, Gustafsson JA 1987 Intracellular localization of the glucocorticoid receptor: evidence for cytoplasmic and nuclear localization. Endocrinology 120:1232–1242[Abstract]
  43. Husmann DA, Wilson CM, McPhaul M, Tilley WD, Wilson JD 1990 Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology 126:2359–2368[Abstract]
  44. Prins GS, Birch L 1993 Immunocytochemical analysis of androgen receptor along the ducts of the separate rat prostate lobes after androgen withdrawal and replacement. Endocrinology 132:169–178[Abstract]
  45. Sar M, Lubahn DB, French FS, Wilson EM 1990 Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127:3180–3186[Abstract]
  46. Orimo A, Inoue S, Ikegami A, Hosoi T, Akishita M, Oushi Y, Muramatsu M, Orimo H 1993 Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun 195:730–736[CrossRef][Medline]
  47. Bayard F, Clamens S, Meggetto F, Blaes N, Delsol G, Faye J-C 1995 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 136:1523–1529[Abstract]
  48. Roberson KM, Edwards DW, Chang GC, Robertson CN 1995 Isolation and characterization of a novel human prostatic stromal culture: DuK50. In Vitro Cell Dev Biol Anim 31:840–845[Medline]
  49. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EM, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1817[Abstract/Free Full Text]
  50. Berns EMJJ, de Boer W, Mulder E 1986 Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9:247–259[Medline]
  51. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C 1996 Genetic change in transforming growth factor ß (TGF-ß) receptor type I gene correlates with insensitivity to TGF-ß1 in human prostate cancer cells. Cancer Res 56:44–48[Abstract/Free Full Text]
  52. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA 1997 The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 138:1145–1150[Abstract/Free Full Text]
  53. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E 1989 Differential effects of transforming growth factor ß on human prostate cancer cells in vitro. Mol Cell Endocrinol 62:79–87[CrossRef][Medline]
  54. Goldstein D, O’Leary M, Mitchen J, Borden EC, Wilding G 1991 Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. J Urol 146:1173–1177[Medline]
  55. Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C 1996 Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res 222:103–110[CrossRef][Medline]
  56. Miniati DN, Chang Y, Shu WP, Peehl DM, Liu BC 1996 Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Cancer Lett 104:137–144[CrossRef][Medline]
  57. Henttu P, Vihko P 1993 Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53:1051–1058[Abstract/Free Full Text]
  58. Schuurmans AL, Bolt J, Veldscholte J, Mulder E 1991 Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40:193–197[CrossRef][Medline]
  59. Syms AJ, Norris JS, Smith RG 1983 Proliferation of a highly androgen-sensitive ductus deferens cell line (DDT1 MF-2) is regulated by glucocorticoids and modulated by growth on collagen. In Vitro 12:929–936
  60. Hall JA, Harris MA, Intres R, Harris SE 1997 Acidic fibroblast growth factor gene 5' non-coding exon and flanking region from hamster DDT1 cells: identification of the promoter region and transcriptional regulation by testosterone and aFGF protein. J Cell Biochem 51:116–127
  61. Hall JA, Harris MA, Malark M, Mansson PE, Zhou H, Harris SE 1990 Characterization of the hamster DDT-1 cell aFGF/HGBF-1 gene and cDNA and its modulation by steroids. J Cell Biochem 43:17–26[CrossRef][Medline]



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H. Wang, K. Song, T. L. Sponseller, and D. Danielpour
Novel Function of Androgen Receptor-associated Protein 55/Hic-5 as a Negative Regulator of Smad3 Signaling
J. Biol. Chem., February 18, 2005; 280(7): 5154 - 5162.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Zhang, Y. Yang, S. Yeh, and C. Chang
ARA67/PAT1 Functions as a Repressor To Suppress Androgen Receptor Transactivation
Mol. Cell. Biol., February 1, 2004; 24(3): 1044 - 1057.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. P. Gelmann
Molecular Biology of the Androgen Receptor
J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M. Haverstick, T. N. Heady, T. L. Macdonald, and L. S. Gray
Inhibition of Human Prostate Cancer Proliferation in Vitro and in a Mouse Model by a Compound Synthesized to Block Ca2+ Entry
Cancer Res., February 1, 2000; 60(4): 1002 - 1008.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
S. C. Sharma, J. W. Clemens, M. D. Pisarska, and J. S. Richards
Expression and Function of Estrogen Receptor Subtypes in Granulosa Cells: Regulation by Estradiol and Forskolin
Endocrinology, September 1, 1999; 140(9): 4320 - 4334.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
W. Y. Chang, L. Birch, C. Woodham, L. I. Gold, and G. S. Prins
Neonatal Estrogen Exposure Alters the Transforming Growth Factor-{beta} Signaling System in the Developing Rat Prostate and Blocks the Transient p21cip1/waf1 Expression Associated with Epithelial Differentiation
Endocrinology, June 1, 1999; 140(6): 2801 - 2813.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map